tbuckley/cabot-search huggingface dataset:
Perspectives on Safety and Efficacy—The BOLD Phase 2 Extension Study of Siponimod in Relapsing-Remitting Multiple Sclerosis
Authors: Edward R. Hammond
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Neonatal units in Wales are understaffed and under-resourced, says report
Authors: Jacqui Wise
Journal: BMJ (2016)

A new report highlights a severe shortage of neonatal nurses and doctors in Wales with services falling short of standards that set out what is needed to deliver safe, high quality care for babies born prematurely or sick.1

The premature and sick baby charity Bliss surveyed all 11 neonatal units and two neonatal transport services in Wales. They found that only two of the neonatal units had enough nurses to staff all their cots, in line with national standards. Nine of 11 units did not have enough nurses with a specialist qualification in neonatal …
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma
Authors: M. Simonelli, P. Zucali, A. Santoro, M.B. Thomas, F.G. de Braud, H. Borghaei, J. Berlin, C.S. Denlinger, C. Noberasco, L. Rimassa, T.-Y. Kim, P.A. English, A. Abbattista, C. Gallo Stampino, M. Carpentieri, J.A. Williams
Journal: Annals of Oncology (2016)
NHS funding at serious risk from Brexit, think tank warns
Authors: Gareth Iacobucci
Journal: BMJ (2016)

The economic fallout from Britain’s vote to leave the European Union (EU) poses a risk to the future funding of the NHS, an analysis by healthcare think tank the Health Foundation has said.

In a briefing published this week,1 the organisation said that the financial pressure on the NHS in England was likely to increase following Brexit, and warned that the government and the country faced “tough decisions” over funding.

It came as the prime minister, David Cameron, rejected a call from the BMA’s chairman, Mark Porter, to invest an additional £350 million (€413m; $460m) a week into the NHS to fulfil a pledge made by Leave campaigners during the referendum debate.2

The Health Foundation’s …
Studies designed to disentangle genetic and environmental variables in schizophrenia: some epistemological questions and answers
Authors: S S Kety
Journal: American Journal of Psychiatry (1976)

The author addresses questions raised by Dr. Lorna S. Benjamin in the preceding paper. He quotes from the original studies to respond to questions regarding statistical logic, the relative prevalence of schizophrenia among half-siblings and parents of index adoptees, and the possible role of socioeconomic status as a confounding variable.
Placebo-controlled randomized study of hydrazine sulfate in lung cancer.
Authors: M P Kosty, J E Herndon, M R Green, O R McIntyre
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.6.1529 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7751903 Placebo-controlled randomized study of hydrazine sulfate in lung cancer. M P KostyxM P KostySearch for articles by this author , J E Herndon 2ndxJ E Herndon 2ndSearch for articles by this author , M R GreenxM R GreenSearch for articles by this author , O R McIntyrexO R McIntyreSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.6.1529 PDF "Placebo-controlled randomized study of hydrazine sulfate in lung cancer.." Journal of Clinical Oncology, 13(6), pp. 1529–1530© 1995 by American Society of Clinical Oncology
PTU-146 The use of diet diaries and a gastric accommodation test prior to hospital discharge for predicting intake after discharge following upper gastrointestinal surgery: Abstract PTU-146 Table 1
Authors: F Froghi, G Sanders, T Wheatley, R Berrisford, P Peyser, J Rahamim, S Lewis
Journal: Gut (2015)

<h3>Introduction</h3> Patients undergoing upper gastrointestinal surgery are often malnourished and following hospital discharge eat poorly despite dietetic input. The ‘slow satiety’ drinking test has been used to assess impaired gastric accommodation in functional dyspepsia. We examined if a drinking test done along with a 2 day diet diary could predict dietary intake post hospital discharge. <h3>Method</h3> Prior to discharge, patients undergoing an oesophagectomy or total gastrectomy for cancer completed a 2 day dietary diary and underwent a gastric accommodation test. The accommodation test comprised of drinking 20 ml/min of polymeric sip feed until they felt comfortably full. After hospital discharge patients completed 2 day dietary diaries at 3, 6 and 12 weeks. The diaries were analysed using Dietplan 6 and tabulated. We calculated energy intake as absolute intake (Kcal) and% of calculated requirement (using the Harris-Benedict formula). The accommodation tests (volume of feed and time taken) were correlated (Pearson’s) with energy intake at hospital discharge. The accommodation test results and energy intake at hospital discharge were also correlated with energy intake at 3, 6 and 12 weeks post discharge. <h3>Results</h3> 28 patients (22 men), median age 66 (IQR: 60–74), were recruited (Oesophagectomy = 18 Gastrectomy 10). There was no correlation between the accommodation test and actual energy intake or% of required energy intake at hospital discharge. Dietary energy intake (Kcal) at hospital discharge did not correlate with post discharge energy intake, but when expressed as a% of calculated requirements there was a correlation at 6 and 12 weeks. The volume of feed consumed and time taken to drink the sip feed for the accommodation test did not correlate with post discharge dietary intake. <h3>Conclusion</h3> Energy intake at hospital discharge was modest and increased slowly to reach 90% of requirements at 12 weeks. There was only a weak correlation between dietary records done just prior to hospital discharge and those done at 6 and 12 weeks. There was no correlation between the gastric accommodation test and post discharge dietary intake. Neither the gastric accommodation test or 2 day dietary records done just before hospital discharge after upper gastrointestinal surgery predicted post discharge dietary intake. <h3>Disclosure of interest</h3> None Declared.
Investigation of 2 Types of Self-administered Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors
Authors: Suzanna M. Zick, Ananda Sen, Gwen K. Wyatt, Susan L. Murphy, J. Todd Arnedt, Richard E. Harris
Journal: JAMA Oncology (2016)

<h3>Importance</h3> Fatigue is a common and debilitating late-term effect of breast cancer that is associated with poor sleep and decreased quality of life, yet therapies remain limited. Acupressure has reduced fatigue in previous small studies, but rigorous clinical trials are needed. <h3>Objectives</h3> To investigate if 6 weeks of 2 types of self-administered acupressure improved fatigue, sleep, and quality of life vs usual care in breast cancer survivors and to determine if changes were sustained during a 4-week washout period. <h3>Design, Setting, and Participants</h3> Phase 3 randomized, single-blind, clinical trial conducted from March 1, 2011, through October 31, 2014. Women were recruited from the Michigan Tumor Registry. <h3>Interventions</h3> Randomization (1:1:1) to 6 weeks of daily self-administered relaxing acupressure, stimulating acupressure, or usual care. <h3>Main Outcomes and Measures</h3> The primary outcome was change in the Brief Fatigue Inventory score from baseline to weeks 6 and 10. Secondary analyses were sleep (Pittsburgh Sleep Quality Index) and quality of life (Long-Term Quality of Life Instrument). <h3>Results</h3> A total of 424 survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously were screened, and 288 were randomized, with 270 receiving relaxing acupressure (n = 94), stimulating acupressure (n = 90), or usual care (n = 86). One woman withdrew owing to bruising at the acupoints. At week 6, the percentages of participants who achieved normal fatigue levels (Brief Fatigue Inventory score &lt;4) were 66.2% (49 of 74) in relaxing acupressure, 60.9% (42 of 70) in stimulating acupressure, and 31.3% (26 of 84) in usual care. At week 10, a total of 56.3% (40 of 71) in relaxing acupressure, 60.9% (42 of 69) in stimulating acupressure, and 30.1% (25 of 83) in usual care continued to have normal fatigue. At neither time point were the 2 acupressure groups significantly different. Relaxing acupressure, but not stimulating acupressure, showed significant improvements in sleep quality compared with usual care at week 6, but not at week 10. Only relaxing acupressure significantly improved quality of life vs usual care at weeks 6 and 10. <h3>Conclusions and Relevance</h3> Both acupressure arms significantly reduced persistent fatigue compared with usual care, but only relaxing acupressure had significant effects on sleep quality and quality of life. Relaxing acupressure offers a possible low-cost option for managing symptoms. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT01281904
SPLENOMEGALY WITH CIRRHOSIS OF THE LIVER.
Authors: H B Maheshwari
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: First report of a randomized controlled trial at 10-years maximum follow-up.
Authors: M. Baum, D. J. Joseph, J. S. Tobias, F. K. Wenz, M. R. Keshtgar, M. Alvarado, M. Bulsara, W. Eiermann, N. R. Williams, J. S. Vaidya
Journal: Journal of Clinical Oncology (2010)

LBA517 Background: After breast conserving surgery, 90% of local recurrences (LR) occur within the index quadrant. Hence, restricting the radiation therapy to the immediate area around the tumour bed after removal of the primary tumour may be adequate (Vaidya JS, et al. Br Cancer.1996;74:820-4) Methods: Having safely piloted a new technique of partial breast irradiation (Vaidya JS, Baum M, Tobias JS et al Ann Oncol 2001;12:1075-80) we launched the TARGIT-A trial in March 2000 comparing TARGIT vs. standard whole breast external beam radiotherapy (EBRT) after breast conserving surgery in patients ≥45 years with invasive duct carcinoma. LR was the primary outcome measure (core protocol: www.thelancet.com/protocol-reviews/99PRT-47 ). Trial accrual from 31 international centers is complete (n=2232), with 80% power to detect a difference in relapse rate of 2.5% - the non-inferiority margin. Results: Median age was 63 (IQR 57-69), median tumor size 13mm (IQR 9-18mm), lymph nodes 17%+ve. Median follow-up is 24.6 months (max 10 years). Wound breakdown or delayed healing were reported in 28 of the TARGIT group and 20 in the EBRT group (p=0.24). RTOG grade 3 toxicity (nil grade 4) was seen in 6 vs. 21 (p=0.004) respectively. Overall local toxicity was equivalent (34/1092 TARGIT v. 41/1096 EBRT, p=0.42). The Kaplan-Meier estimate of LR in the breast, was 0.31% (CI 0.08-1.26) for TARGIT versus 0.29% for EBRT (CI 0.07-1.16) at 24 months. Conclusions: In the TARGIT group, the radiotherapy toxicity was significantly lower than in the EBRT group, while the increase in wound complications was not statistically significant. This analysis suggests that at a median follow-up of 24 months the local control with TARGIT is comparable to EBRT. Longer term follow-up is essential and accrual in similar studies is encouraged. [Table: see text]
Can oncologists add?
Authors: M E Lippman
Journal: Journal of Clinical Oncology (1989)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1989.7.6.698 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2715801 Can oncologists add? M E LippmanxM E LippmanSearch for articles by this author Show More Georgetown University Medical Center, Washington, DC. https://doi.org/10.1200/JCO.1989.7.6.698 PDF "Can oncologists add?." Journal of Clinical Oncology, 7(6), pp. 698–699© 1989 by American Society of Clinical Oncology
Using Bayesian Adaptive Trial Designs for Comparative Effectiveness Research: A Virtual Trial Execution
Authors: Bryan R. Luce, Jason T. Connor, Kristine R. Broglio, C. Daniel Mullins, K. Jack Ishak, Elijah Saunders, Barry R. Davis
Journal: Annals of Internal Medicine (2016)

Bayesian and adaptive clinical trial designs offer the potential for more efficient processes that result in lower sample sizes and shorter trial durations than traditional designs.To explore the use and potential benefits of Bayesian adaptive clinical trial designs in comparative effectiveness research.Virtual execution of ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) as if it had been done according to a Bayesian adaptive trial design.Comparative effectiveness trial of antihypertensive medications.Patient data sampled from the more than 42 000 patients enrolled in ALLHAT with publicly available data.Number of patients randomly assigned between groups, trial duration, observed numbers of events, and overall trial results and conclusions.The Bayesian adaptive approach and original design yielded similar overall trial conclusions. The Bayesian adaptive trial randomly assigned more patients to the better-performing group and would probably have ended slightly earlier.This virtual trial execution required limited resampling of ALLHAT patients for inclusion in RE-ADAPT (REsearch in ADAptive methods for Pragmatic Trials). Involvement of a data monitoring committee and other trial logistics were not considered.In a comparative effectiveness research trial, Bayesian adaptive trial designs are a feasible approach and potentially generate earlier results and allocate more patients to better-performing groups.National Heart, Lung, and Blood Institute.
Abstract 12098: Influence of Recent Hospitalization for Non-coronary Events on the Use of Preventive Medications for Coronary Artery Disease
Authors: Steven M Bradley, Chris L Bryson, Charles Maynard, Thomas M Maddox, Stephan D Fihn
Journal: Circulation (2010)

Background: Increasingly, comprehensive patient care is the goal of high-quality systems instead of diagnosis or procedure driven care. The current emphasis on secondary prevention of coronary arte...
Lichenoid drug eruption associated with Bendamustine
Authors: Y Kusano, Y Terui, M Yokoyama, K Hatake
Journal: Blood Cancer Journal (2016)

A 65-year-old man had relapsed follicular lymphoma.When he suffered a fifth relapse, he received a regimen containing bendamustine and rituximab (BR).Four weeks later, he presented with systemic erythema, swelling and bullous lesions of lips, the oral cavity, andnasal mucosa and eye pain.He could not open his mouth and had severe pain.Steven-Johnson syndrome/toxic epidermal necrolysis was diagnosed.With corticosteroid treatment and intravenous administration of oxycodone, he recovered for 2 weeks and was discharged.However, 10 days later, bullous lesions appeared again at lips (Figure 1a), oral cavity and genital mucosa.In addition, numerous erythematous plaques with Koebner's phenomenon were observed on his trunk (Figure 1b).Blood test, in which antibody was measured, showed neither candidiasis nor pemphigus.Microscopic examination revealed interface dermatitis with necrotic keratinocytes, which was a histological feature of lichenoid drug eruption.Prednisone 5 mg daily was initiated for his lichenoid drug eruption.Although with 4-month treatment his manifestation recovered little by little, mucosal lesions were intractable.His lymphoma was observed afterward because he achieved partial response by one cycle of BR.One year later, however, his wife became aware of his changing mental status.He eventually died of central nervous system involvement in lymphoma.Lichenoid drug eruption, also known as drug-induced lichen planus, is an uncommon cutaneous adverse effect of several drugs. 1,2It is characterized by a symmetric eruption resembling lichen planus on the trunk and extremities.Lichenoid drug eruption may sometimes be difficult to differentiate from Stevens-Johnson syndrome/toxic epidermal necrolysis, in particular, at the time of onset. 3However, interface dermatitis is found in histological appearance, resulting in difference between lichenoid drug eruption and Steven-Johnson syndrome. 4In general, lichenoid drug eruptions resolve spontaneously in a few weeks to a few months with the discontinuation of the offending drug. 5On the other hand, in our case, systemic corticosteroid was refractory to eruptions.Although the mechanism of lichenoid drug reaction has been unknown, lichenoid drug eruption is thought to be associated with activation of CD8 autocytotoxic T lymphocytes against epidermal cells.Bendamustine induced prolonged lymphocytopenia, inparticular CD4 T lymphocytes.There was no understanding between bendamustine and uncommon clinical course of lichenoid drug eruption in our case.To the best our knowledge, this is a first report of lichenoid drug eruption associated with bendamustine.
Time to Complete Remission As a Function of Kinetics of White Blood Cell Elimination and Recovery in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy
Authors: Umera Thebo, Tomas Radivoyevitch, Surbhi Sidana, Cassandra Fincher, Amanda L. Maggiotto, Yogen Saunthararajah, Anjali S. Advani, Aaron T. Gerds, Hetty E. Carraway, Betty K. Hamilton, Matt E. Kalaycio, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Sudipto Mukherjee
Journal: Blood (2014)
Functional Inhibition of Mesenchymal Stem and Progenitor Cells (MSPC) Significantly Contributes to Hematopoietic Insufficiency with Acute Myeloid Leukemia (AML)
Authors: Stefanie Geyh, Manuel Rodríguez-Paredes, Cyrus Khandanpour, Ron-Patrick Cadeddu, Paul Jäger, Christoph Zilkens, Ulrich Dührsen, C. Matthias Wilk, Roland Fenk, Norbert Gattermann, Ulrich Germing, Guido Kobbe, Frank Lyko, Rainer Haas, Thomas Schroeder
Journal: Blood (2014)
P-282 JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer
Authors: Van Cutsem Eric, Wyrwicz Lucjan, Lee Keun-Wook, Ciardiello Fortunato, Guimbaud Rosine, Taieb Julien, Gurtler Jayne, Boku Narikazu, Xiong Huiling, Zhang Jenny, Cuillerot Jean-Marie, Bang Yung-Jue
Journal: Annals of Oncology (2016)
Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments
Authors: Anna Kalff, Nola Kennedy, Patricia A. Walker, Tiffany T. Khong, Anthony Schwarer, Andrew W. Roberts, Philip Campbell, Robin Filshie, Angela Smiley, Malgorzata Gorniak, Marion Black, Nicole Jenkins, Geoffrey Raines, Andrew Spencer
Journal: Blood (2014)
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction
Authors: Sanjiv J. Shah, Dalane W. Kitzman, Barry A. Borlaug, Loek van Heerebeek, Michael R. Zile, David A. Kass, Walter J. Paulus
Journal: Circulation (2016)

Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity. In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. The latter affects left ventricular diastolic dysfunction through macrophage infiltration, resulting in interstitial fibrosis, and through altered paracrine signaling to cardiomyocytes, which become hypertrophied and stiff because of low nitric oxide and cyclic guanosine monophosphate. Systemic inflammation also affects other organs such as lungs, skeletal muscle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium retention. Individual steps of these signaling cascades can be targeted by specific interventions: metabolic risk by caloric restriction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxide bioavailability by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by spironolactone. Because of phenotypic diversity in HFpEF, personalized therapeutic strategies are proposed, which are configured in a matrix with HFpEF presentations in the abscissa and HFpEF predispositions in the ordinate.